Iradimed (NASDAQ: IRMD) director receives 1,026 restricted stock units

Rhea-AI Filing Summary

Iradimed Corporation reported that one of its directors received an equity award of 1,026 restricted stock units (RSUs) on December 11, 2025 under the company’s 2023 Equity Incentive Plan. Each RSU converts into one share of common stock when it vests, so this grant represents the right to receive the same number of common shares in the future.

The RSUs vest in two equal annual installments beginning on December 11, 2026, aligning the director’s compensation with longer-term company performance. After this grant, the director beneficially owns 1,932 RSUs, all held as a direct ownership interest.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HAWKINS JAMES B

(Last) (First) (Middle)

C/O IRADIMED CORPORATION

12705 INGENUITY DRIVE

(Street)

ORLANDO FL 32826

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IRADIMED CORP [ IRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
12/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	12/11/2025		A		1,026		(2)	(2)	Common Stock	1,026	$0	1,932	D

Explanation of Responses:

1. Restricted stock units convert into common stock on a one-for-one basis.

2. On December 11, 2025, the reporting person received restricted stock units under Iradimed Corporation's 2023 Equity Incentive Plan. The restricted stock units vest in two equal annual installments beginning on December 11, 2026. Upon vesting, the reporting person will receive a number of shares of common stock equal to the number of restricted stock units that have vested.

	/s/ James B. Hawkins	12/15/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Iradimed (IRMD) report in this Form 4?

The Form 4 reports that a director of Iradimed Corporation (IRMD) received 1,026 restricted stock units (RSUs) on December 11, 2025 as an equity award.

How do the Iradimed (IRMD) restricted stock units from this grant vest?

The 1,026 RSUs vest in two equal annual installments, with vesting beginning on December 11, 2026. Each installment covers half of the total grant.

What do the Iradimed (IRMD) RSUs convert into when they vest?

Each restricted stock unit converts into one share of Iradimed common stock upon vesting, on a one-for-one basis as stated in the disclosure.

How many derivative securities does the Iradimed (IRMD) director own after this transaction?

Following the reported transaction, the director beneficially owns 1,932 restricted stock units, all reported as direct ownership.

Under which plan were the Iradimed (IRMD) RSUs granted to the director?

The 1,026 RSUs were granted under Iradimed Corporation’s 2023 Equity Incentive Plan as part of the director’s equity compensation.

Did the Iradimed (IRMD) director pay a purchase price for these RSUs?

No cash purchase was indicated. The RSUs were granted as compensation with a reported price of $0 for the derivative security in the Form 4 table.